Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Drug treatment of glaucoma focuses on reducing / controlling IOP and preserving visual function. Given the availability of therapies from several drug classes (e.g., PGAs, beta blockers, FDCs), multiple factors (e.g., efficacy, safety / tolerability, patient convenience and compliance, cost) determine the treatment approach. Even with multiple generic therapies available, branded therapies (e.g., Allergan’s Lumigan and Combigan, Novartis’s Travatan Z) still play an important role in glaucoma treatment. Given the continued use of branded therapies and the entry of new agents to the market (e.g., Bausch + Lomb’s Vyzulta, Aerie Pharmaceuticals’ Rhopressa), it is essential to understand physicians’ actual prescribing behavior for glaucoma.
Geography: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Lumigan, Travatan Z, Combigan, Cosopt PF, Simbrinza, Alphagan P, Azopt, Vyzulta, Rhopressa, latanoprost, timolol maleate
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Already a Client? Log in to access this report.
Himanshu is a Lead Analyst in the CNS/Ophthalmology team at Decision Resources Group, and has authored content for indications including age-related macular degeneration, diabetic retinopathy/diabetic macular edema, and unipolar depression. He comes with eight years of experience working on commercial assessment projects, including opportunity assessments, market intelligence, disease narratives, epi-based forecasts, patent research, and social media analysis, across multiple therapy areas. He holds a degree in Pharmacology from the National Institute of Pharmaceutical Education and Research (NIPER) in India and an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.